Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients

被引：21
作者：
Song, Jian-Yuan [1 ]
Chen, Ming-Qiu [1 ]
Guo, Jing-Hua [1 ]
Lian, Shi-Feng [1 ]
Xu, Ben-Hua [1 ]
机构：
[1] Fujian Med Univ, Union Hosp, Dept Radiat Oncol, Fuzhou, Fujian, Peoples R China
来源：
MEDICINE | 2018年 / 97卷 / 04期
关键词：
CA19-9; metastatic pancreatic cancer; neutrophil-to-lymphocyte ratio; prognostic factor; CARBOHYDRATE ANTIGEN 19-9; LEVEL; STATISTICS; SURVIVAL; MARKER;
D O I：
10.1097/MD.0000000000009707
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The aim of this study was to explore the role of combined pretreatment serum carbohydrate antigen 19-9 (CA19-9) and neutrophil-tolymphocyte ratio (NLR) as potential prognostic factors in metastatic pancreatic cancer patients. We investigated pretreatment serum CA19-9 and NLR in 59 metastatic pancreatic cancer patients, determined the patients' thresholds by receiver operating characteristic curve analysis, and assessed their prognostic values by Kaplan-Meier curve and Cox regression models. Results of multivariate analysis showed high CA19-9, high NLR, and high score (the scoring system of CA19-9 and NLR) were significantly correlated with overall survival. Area under the curve of the scoring system was higher than that of CA19-9 or NLR. Combined pretreatment serum CA19-9 and NLR is a better prognostic biomarker of metastatic pancreatic cancer patients than CA19-9 or NLR alone.
引用
收藏
页数：5
相关论文
共 25 条
[1]   Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer [J].
Asaoka, Tadafumi ;
Miyamoto, Atsushi ;
Maeda, Sakae ;
Tsujie, Masanori ;
Hama, Naoki ;
Yamamoto, Kazuyoshi ;
Miyake, Masakazu ;
Haraguchi, Naotsugu ;
Nishikawa, Kazuhiro ;
Hirao, Motohiro ;
Ikeda, Masataka ;
Sekimoto, Mitsugu ;
Nakamori, Shoji .
PANCREATOLOGY, 2016, 16 (03) :434-440
[2]   Inflammation and cancer: back to Virchow? [J].
Balkwill, F ;
Mantovani, A .
LANCET, 2001, 357 (9255) :539-545
[3]   Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer [J].
Boeck, Stefan ;
Stieber, Petra ;
Holdenrieder, Stefan ;
Wilkowski, Ralf ;
Heinemann, Volker .
ONCOLOGY, 2006, 70 (04) :255-264
[4]   Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer [J].
Carruthers, R. ;
Tho, L. M. ;
Brown, J. ;
Kakumanu, S. ;
McCartney, E. ;
McDonald, A. C. .
COLORECTAL DISEASE, 2012, 14 (10) :E701-E707
[5]   A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer [J].
Chen, Yuntao ;
Shao, Zhenyi ;
Chen, Wen ;
Xie, Hua ;
Wu, Zhenyu ;
Qin, Guoyou ;
Zhao, Naiqing .
ONCOTARGET, 2017, 8 (18) :29925-29934
[6]  
Gu Yu-Lei, 2015, Asian Pac J Cancer Prev, V16, P6569
[7]   Hallmarks of Cancer: The Next Generation [J].
Hanahan, Douglas ;
Weinberg, Robert A. .
CELL, 2011, 144 (05) :646-674
[8]   Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study [J].
Imaoka, Hiroshi ;
Shimizu, Yasuhiro ;
Senda, Yoshiki ;
Natsume, Seiji ;
Mizuno, Nobumasa ;
Hara, Kazuo ;
Hijioka, Susumu ;
Hieda, Nobuhiro ;
Tajika, Masahiro ;
Tanaka, Tsutomu ;
Ishihara, Makoto ;
Niwa, Yasumasa ;
Yamao, Kenji .
PANCREATOLOGY, 2016, 16 (04) :658-664
[9]   Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: a retrospective study in a single institute in Japan [J].
Inoue, Dai ;
Ozaka, Masato ;
Matsuyama, Masato ;
Yamada, Ikuhiro ;
Takano, Koichi ;
Saiura, Akio ;
Ishii, Hiroshi .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (01) :61-66
[10]   Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy [J].
Kim, Yi-Jun ;
Koh, Hyeon Kang ;
Chie, Eui Kyu ;
Oh, Do-Youn ;
Bang, Yung-Jue ;
Nam, Eun Mi ;
Kim, Kyubo .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (06) :1069-1075
123